Jasper Therapeutics
JSPR
65 hedge funds and large institutions have $69.5M invested in Jasper Therapeutics in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 20 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
24% more capital invested
Capital invested by funds: $56.1M → $69.5M (+$13.4M)
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
3.56% less ownership
Funds ownership: 86.87% → 83.31% (-3.6%)
4% less funds holding
Funds holding: 68 → 65 (-3)
15% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 20
23% less call options, than puts
Call options by funds: $232K | Put options by funds: $302K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
+$959K |
| 2 |
Jane Street
New York
|
+$654K |
| 3 |
Millennium Management
New York
|
+$587K |
| 4 |
Morgan Stanley
New York
|
+$570K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$425K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.77M |
| 2 |
State Street
Boston,
Massachusetts
|
-$902K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$653K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$583K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$529K |
JSPR Hedge Fund Activity: Q2 2025 in Review
65 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q2 2025, worth a combined $69.5M — up 24% from $56.1M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of JSPR and 17 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 17 added.
The largest buyer was Kingdon Capital Management, adding an estimated $959K. The largest seller was BlackRock, cutting an estimated $2.77M.
- 65 institutional investors held Jasper Therapeutics (JSPR) as of Q2 2025, down from 68 in Q1 2025.
- Funds reported $69.5M of Jasper Therapeutics stock for Q2 2025, up 24% quarter-over-quarter.
- 17 funds opened new Jasper Therapeutics positions in Q2 2025 and 20 closed out, a net change of -3 holders.
- The largest Jasper Therapeutics buyer in Q2 2025 was Kingdon Capital Management, an estimated $959K added.
- The largest Jasper Therapeutics seller in Q2 2025 was BlackRock, an estimated $2.77M sold.
Based on aggregated 13F filings for Q2 2025.